These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38501063)

  • 1. CD39 expression defines exhausted CD4
    Duan ZQ; Li YX; Qiu Y; Shen Y; Wang Y; Zhang YY; Zhu BH; Yu XH; Tan XL; Chen W; Zhuang Y; Cheng P; Zhang WJ; Zou QM; Ma DY; Peng LS
    Clin Transl Immunology; 2024; 13(3):e1499. PubMed ID: 38501063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD39
    Shen Y; Qiu Y; Duan ZQ; Li YX; Wang Y; Zhang YY; Zhu BH; Yu XH; Tan XL; Chen W; Zhuang Y; Zou QM; Ma DY; Peng LS
    Pharmacol Res; 2024 Apr; 202():107122. PubMed ID: 38428703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased tumor-infiltrating CD45RA
    Mao FY; Kong H; Zhao YL; Peng LS; Chen W; Zhang JY; Cheng P; Wang TT; Lv YP; Teng YS; Fu XL; Liu YG; Wu XL; Hao CJ; You N; Luo P; Yu PW; Zou QM; Guo G; Zhuang Y
    Cell Death Dis; 2017 Aug; 8(8):e3002. PubMed ID: 28817117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD39
    Bossio SN; Abrate C; Tosello Boari J; Rodriguez C; Canale FP; Ramello MC; Brunotto V; Richer W; Rocha D; Sedlik C; Vincent-Salomon A; Borcoman E; Del Castillo A; Gruppi A; Fernandez E; Acosta Rodríguez EV; Piaggio E; Montes CL
    Oncoimmunology; 2023; 12(1):2246319. PubMed ID: 37885970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically driven CD39 expression shapes human tumor-infiltrating CD8
    Gallerano D; Ciminati S; Grimaldi A; Piconese S; Cammarata I; Focaccetti C; Pacella I; Accapezzato D; Lancellotti F; Sacco L; Caronna R; Melaiu O; Fruci D; D'Oria V; Manzi E; Sagnotta A; Parrino C; Coletta D; Peruzzi G; Terenzi V; Battisti A; Cassoni A; Fadda MT; Brozzetti S; Fazzi K; Grazi GL; Valentini V; Chirletti P; Polimeni A; Barnaba V; Timperi E
    Int J Cancer; 2020 Nov; 147(9):2597-2610. PubMed ID: 32483858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
    Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
    PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Exhausted PD-1
    Martinez-Gomez C; Michelas M; Scarlata CM; Salvioni A; Gomez-Roca C; Sarradin V; Lauzéral-Vizcaino F; Féliu V; Dupret-Bories A; Ferron G; Sarini J; Devaud C; Delord JP; Balança CC; Martinez A; Ayyoub M
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of tumor-reactive CD4
    Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39
    Leem G; Park J; Jeon M; Kim ES; Kim SW; Lee YJ; Choi SJ; Choi B; Park S; Ju YS; Jung I; Kim S; Shin EC; Lee JY; Park SH
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
    Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
    Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bystander CD4
    Li S; Zhuang S; Heit A; Koo SL; Tan AC; Chow IT; Kwok WW; Tan IB; Tan DSW; Simoni Y; Newell EW
    Oncoimmunology; 2022; 11(1):2012961. PubMed ID: 36524209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
    Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
    JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of the CD8
    Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
    Front Immunol; 2021; 12():687296. PubMed ID: 34177939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enrichment of Inflammatory IL-17 and TNF-α Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1.
    Dunne MR; Ryan C; Nolan B; Tosetto M; Geraghty R; Winter DC; O'Connell PR; Hyland JM; Doherty GA; Sheahan K; Ryan EJ; Fletcher JM
    Front Oncol; 2016; 6():50. PubMed ID: 27014625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Location of CD39
    Koppensteiner L; Mathieson L; Pattle S; Dorward DA; O'Connor R; Akram AR
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating mycobacterial-reactive CD4+ T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection.
    Kim K; Perera R; Tan DB; Fernandez S; Seddiki N; Waring J; French MA
    Tuberculosis (Edinb); 2014 Sep; 94(5):494-501. PubMed ID: 25095750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD39 Identifies the CD4
    Kortekaas KE; Santegoets SJ; Sturm G; Ehsan I; van Egmond SL; Finotello F; Trajanoski Z; Welters MJP; van Poelgeest MIE; van der Burg SH
    Cancer Immunol Res; 2020 Oct; 8(10):1311-1321. PubMed ID: 32759363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma.
    Brauneck F; Weimer P; Schulze Zur Wiesch J; Weisel K; Leypoldt L; Vohwinkel G; Fritzsche B; Bokemeyer C; Wellbrock J; Fiedler W
    Front Med (Lausanne); 2021; 8():763773. PubMed ID: 34820398
    [No Abstract]   [Full Text] [Related]  

  • 20. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
    Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
    Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.